COMPANY
Eluciderm
Eluciderm has developed a platform of small molecules that selectively modulate multiple Poly(ADP-ribose) polymerase (PARP) enzymes. From company website Source · Oct 12, 2026
Timeline
- Trial start Phase 1/Phase 2: Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07396376 | Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers | Phase 1/Phase 2 | Recruiting | Nov 10, 2025 | Jun 1, 2026 (estimated) |